Copyright © 2007 Elsevier Ltd All rights reserved.
Molecular design of anti-MRSA agents based on the anacardic acid scaffold
Received 21 November 2006;
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Abstract
A series of anacardic acid analogues possessing different side chains viz. phenolic, branched, and alicyclic were synthesized and their antibacterial activity tested against methicillin-resistant Staphylococcus aureus (MRSA). The maximum activity against this bacterium occurred with the branched side-chain analogue, 6-(4′,8′-dimethylnonyl)salicylic acid, and the alicyclic side-chain analogue, 6-cyclododecylmethyl salicylic acid, with the minimum inhibitory concentration (MIC) of 0.39 μg/mL, respectively. This activity was superior to that of the most potent antibacterial anacardic acid isolated from the cashew Anacardium occidentale (Anacardiaceae), apple and nut, that is, the 6-[8′(Z),11′(Z),14′-pentadecatrienyl]salicylic acid.
Keywords: Methicillin-resistant Staphylococcus aureus (MRSA); Antibacterial; Anacardic acid analogue; 6-(4′,8′-Dimethylnonyl)salicylic acid







E-mail Article
Add to my Quick Links

Cited By in Scopus (1)






